32
Participants
Start Date
June 30, 2006
Primary Completion Date
December 31, 2009
Study Completion Date
August 31, 2010
catumaxomab
Catumaxomab is administered intraperitoneally via an indwelling catheter (or port) as a 3-hour infusion 4 times (Days 0, 3, 7, and 10) in ascending doses (10 mcg, 20 mcg, 50 mcg, and 150 mcg, respectively).
University of Arizona Cancer Center, Tucson
University of San Diego, La Jolla
Stanford University Hospital and Clinics, Stanford
University of Miami, Miami
Florida Hospital Cancer Center, Orlando
Northern Indiana Cancer Research Consortium, South Bend
University of Louisville Cancer Center, Louisville
Johns Hopkins Medical Institute, Baltimore
Dana Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Wayne State University, Detroit
Dartmouth-Hitchock Medical Center, Lebanon
Columbia University Cancer center, New York
Wake-Forest University, Winston-Salem
University of Oklahoma Health Science Center, Oklahoma City
Magee Women's Hospital, University of Pittsburgh, Pittsburgh
The Methodist Hospital, Houston
Huntsman Cancer Institute, Salt Lake City
Lead Sponsor
Collaborators (1)
Fresenius Biotech North America
INDUSTRY
Neovii Biotech
INDUSTRY